Domestic Innovative Drug Sector Sees Funding Surge as Multiple Biotechs Secure Major Capital Infusions

　　【Pharmaceutical Network Industry Dynamics] According to the review, yesterday (November 10), several innovative drug companies in China announced significant financing. This series of financing events not only injected strong momentum into the companies' own development but also demonstrated the capital market's high recognition of the development potential in China's innovative drug sector, injecting new vitality into the continuous upgrading of China's biopharmaceutical industry.
 

Among them, DeliNova Therapeutics, a biotechnology company focused on innovative in vivo CAR-T therapies, has successfully completed seed and angel financing of nearly 60 million yuan. The funds will be used to accelerate the evolution of its core technology platform, team building, and the clinical translation and development of its lead candidate product in areas such as hematologic tumors and autoimmune diseases.
 

Data shows that DeliNova Therapeutics focuses on the core platforms of "multi-dimensional" engineered viral vector modification and T-cell specific delivery. By precisely modifying lentiviral vectors, the company directly, efficiently, and specifically transduces T cells in vivo to generate CAR-T cells. The company’s lead pipeline, based on clinically validated targets, is expected to soon initiate investigator-initiated trials (IIT) for hematological tumors, while also entering the IND preparation phase. The IIT for autoimmune diseases and solid tumors is planned to launch in 2026. In the future, DeliNova Therapeutics will further expand its range of targeted platform technologies for various immune cells and explore application potential in chronic disease fields such as anti-aging.
 

DeliNova Therapeutics Announces Completion of Multi-Million Dollar Series A Financing Round; Funds to Advance Innovative Pipeline into Critical Clinical Stages, Accelerate Development of Dry-Wet Closed-Loop Antibody Design Intelligence Platform, and Expand In-Depth Collaborations with Global Biopharmaceutical Companies.
 

Data shows that DeliNova Therapeutics has built an intelligent antibody design agent with autonomous evolution capabilities. By integrating high-throughput single-cell functional screening and an intracellular yeast-directed evolution platform, the company is transforming the paradigm of functional data generation from the ground up. This creates a high-throughput, information-rich experimental data flywheel for the intelligent agent, enabling differentiated antibody discovery and optimization capabilities to develop an antibody drug pipeline. The company is strategically positioned in several high-value, high-challenge areas, including epitope-specific targeting antibodies, multi-specific antibodies, endocytic antibodies, and pH-switchable antibodies. This allows the molecules designed by the intelligent agent to achieve higher safety and superior efficacy, delivering better therapeutic effects and differentiated clinical advantages.
 

Cornerstone Robotics announces the completion of a new round of over-subscribed financing worth approximately 200 million US dollars. The proceeds from this funding will mainly be used to accelerate commercialization processes in China and overseas, and to promote the research and development of next-generation products and clinical registration.
 

Data shows that Cornerstone Robotics has grown into an innovative surgical company in China through full-stack self-research and deep integration.RobotEnterprise. The company's core product, Sentire® Laparoscopic Surgical Robot, has not only been approved for marketing by the China National Medical Products Administration (NMPA) but has also been put into clinical application in multiple hospitals in mainland China, Hong Kong, and Europe. The company is continuously transforming its independent innovation achievements into a driving force for the development of the global intelligent medical ecosystem.
 

The recent surge in massive funding for multiple innovative drug companies reflects several industry trends. With the continuous increase in people's health demands and the rapid development of biopharmaceutical technologies, the innovative drug sector has become a focal point for capital markets, showing broad prospects for industry growth. Moreover, domestic innovative drug companies have made continuous breakthroughs in core technology research and development as well as product pipeline layouts, gradually gaining strength and earning widespread recognition from the capital markets. Meanwhile, strong policy support for the biopharmaceutical industry has also created a favorable environment for the development of innovative drug enterprises, further fueling investment enthusiasm in the innovative drug sector from the capital markets.
 

Looking ahead, with the support of substantial financing, these innovative drug companies will take more solid steps in technology research and development, product transformation, and market expansion. At the same time, this will also drive the development of the entire innovative drug industry in China, promoting China's biopharmaceutical industry to advance towards higher quality and a higher level.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.